Approval of Drugs Which May Be Used by Certain Optometrists

[46 Pa.B. 7048]
[Saturday, November 5, 2016]

 Under the Optometric Practice and Licensure Act (act) (63 P.S. §§ 244.1—244.12), as amended by the act of December 16, 2002 (P.L. 1950, No. 225) (Act 225), the Secretary of Health (Secretary) has the authority to approve drugs for use in the ''practice of optometry'' as defined in Act 225. The State Board of Optometry, through the Secretary of State, sent the Secretary a letter on August 22, 2016, and requested that the Secretary approve the use of the following drug. Act 225 requires that the Secretary, within 90 days of the receipt of the list of drugs, approve or disapprove for good cause each drug. The Secretary has found good cause to approve the use of the following drug in the practice of optometry:

 Lifitegrast (Xiidra®) ophthalmic solution

 The approval of the use of this drug is effective upon publication of this notice in the Pennsylvania Bulletin.

 Persons with a disability who require an alternative format of this notice (for example, large print, audiotape or Braille) should contact Susan Coble, Director, Bureau of Community Program Licensure and Certification, 132 Kline Plaza, Suite A, Harrisburg, PA 17104, (717) 783-8665 for speech and/or hearing impaired persons V/TT (717) 783-6514 or the Pennsylvania AT&T Relay Service at (800) 654-5984 (TT).


[Pa.B. Doc. No. 16-1913. Filed for public inspection November 4, 2016, 9:00 a.m.]

No part of the information on this site may be reproduced for profit or sold for profit.

This material has been drawn directly from the official Pennsylvania Bulletin full text database. Due to the limitations of HTML or differences in display capabilities of different browsers, this version may differ slightly from the official printed version.